Clinical trials: Botox
Myofascial Pain Syndromes
A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome.
The purpose of this study is to determine whether electrical stimulation enhances the effect of botulinum toxin type A (Dysport®) on myofascial pain syndrome.
- Trial name
- NCT00246142
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Ipsen
Neurogenic Detrusor Overactivity
Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity
This is a prospective, multicentre (7 sites), randomized, double-blind, study comparing intravesical injection of BOTOX to placebo in 56 subjects with NDO secondary to spinal cord injury or multiple sclerosis.
- Trial name
- NCT01091727
- Testing
- Botulinum toxin A
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- Sunnybrook Health Sciences Centre
BOTOX, Percutaneous Tibial Nerve Stimulation
IDB Injection Combined With PTNS for Managing Children With OAB Not Responding to Monotherapy
This study aimed to evaluate the outcome of simultaneous intradetrusor BOTOX (IDB) injection and Percutaneous tibial nerve stimulation (PTNS) for management of children with recurrent wetness since at least 6 months.
- Trial name
- NCT05911594
- Testing
- Solifenacin group, Percutaneous tibial nerve stimulation group, Intradetrusor BOTOX group
- Where
- Egypt
- Volunteers
- 128 people
- Sponsor
- Benha University
Platysma Prominence
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
This is a Phase 3, open-label extension study to evaluate the long-term safety of repeat BOTOX treatments in adult participants with Platysma Prominence.
- Trial name
- NCT05134649
- Testing
- OnabotulinumtoxinA
- Where
- 29 sites in United States, Canada
- Volunteers
- 292 people
- Sponsor
- AbbVie
Interstitial Cystitis, Bladder Pain Syndrome
Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome
Recognition of interstitial cystitis (IC)/bladder pain syndrome (BPS) is increasing. There is a dire need to develop effective treatment options for these patients as it manifests as more than a physical disease, affecting…
- Trial name
- NCT04401176
- Testing
- Heparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Walter Reed National Military Medical Center
Overactive Bladder, Neurogenic Bladder
A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections
The goal of this clinical trial is to assess if a mix of nitrous oxide and oxygen can improve pain control during bladder Botox injections.
- Conditions
- Overactive Bladder, Neurogenic Bladder, Urge Incontinence, Pain
- Trial name
- NCT07387315
- Testing
- Pro-Nox Nitrous Oxide/Oxygen Delivery System, Standard Care for Bladder Botox Injection
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- TriHealth Inc.
Lower Limb Spasticity Due to Cerebral Palsy
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) are effective in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollable muscle…
- Trial name
- NCT01893411
- Testing
- IncobotulinumtoxinA (16 Units per kg body weight), IncobotulinumtoxinA (12 Units per kg body weight), IncobotulinumtoxinA (4 Units per kg body weight)
- Where
- 53 sites in Austria, Czechia and 12 more
- Volunteers
- 311 people
- Sponsor
- Merz Pharmaceuticals GmbH
Blepharospasm
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.
- Trial name
- NCT00234507
- Testing
- Botulinum toxin type A
- Where
- 14 sites in United States
- Volunteers
- 120 people
- Sponsor
- Ipsen
Benign Prostatic Hyperplasia (BPH), Benign Prostatic Enlargement (BPE)
Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy
The injection of botulinum neurotoxin A into the prostate represents an alternative, minimal invasive treatment in patient with lower urinary tract symptoms (LUTS) associated to benign prostatic hyperplasia (BPH).
- Trial name
- NCT01566292
- Testing
- BOTOX
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Catholic University of the Sacred Heart
Benign Prostatic Hyperplasia
Effect of 50 and 100 IU Doses of Botox A Toxin Injection in BPH Patients.
The primary objective of this study is to compare the efficacy and safety of a single injection of 50 U and 100 U doses of BoNT-A for the treatment of BPH-associated LUTS.
- Trial name
- NCT02524236
- Testing
- Botox injection in the prostate
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Beni-Suef University
Glabellar Frown Lines
The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines
A Phase Ⅲ Clinical Trial to Compare the Safety and Efficacy of Hutox versus Botox® in Subject with Moderate to Severe Glabellar Lines
- Trial name
- NCT03440671
- Testing
- Hutox Inj, Botox Inj
- Where
- South Korea
- Volunteers
- 260 people
- Sponsor
- Huons Co., Ltd.
Urinary Bladder, Overactive
Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
GSK1358820 is a botulinum neurotoxin A complex that has been approved for the treatment of overactive bladder (OAB) in several countries, however, it has not been approved for OAB treatment in Japan.
- Trial name
- NCT02820844
- Testing
- GSK1358820, Antibiotic therapy, Bladder diary
- Where
- 48 sites in Japan
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Other Infantile Cerebral Palsy
Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy
To compare the safety and efficacy of Botulax Inj.®(Botulinum toxin type A, Hugel, South Korea) with Botox Inj.® (Botulinum toxin type A, Allergan, USA) in the treatment of cerebral palsy in children.
- Trial name
- NCT01787344
- Testing
- Botulinum Toxin Type A(Botox®), Botulinum toxin type A(Botulax®)
- Where
- 6 sites in South Korea
- Volunteers
- 144 people
- Sponsor
- Hugel
Healthy
Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products
Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening.
- Trial name
- NCT00515944
- Testing
- Botulinum neurotoxin type A, free of complexing proteins
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Neuropathic Pain
Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain
Onabotulinum toxin type A (BoNT-A) is a potent neurotoxin that has been reported to have an effect on afferent (sensory) neurons independent of its action on muscle tone and secretory glands at the periphery.In human studies, the…
- Trial name
- NCT03848143
- Testing
- onabotulinum toxin A
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Isabel Moreno Hay
Glabellar Lines
Treatment of Moderate to Severe Glabellar Lines (BMI2006)
A multicenter, double-blind, randomized, parallel design, active control, phase 3 clinical trial to evaluate the efficacy and safety of 100 units of BMI 2006 and Botox® in adult patients in need of moderate or severe glabellar…
- Trial name
- BMI2006 (NCT05531968)
- Testing
- BMI2006, BOTOX®
- Where
- 3 sites in South Korea
- Volunteers
- 278 people
- Sponsor
- BMI Korea
Premature (Early) Ejaculation
Dual-Site Botulinum Toxin Type A Injection for Lifelong Premature Ejaculation
Premature ejaculation is a common sexual condition that can cause distress for men and their partners. Different treatments are available, but some men do not respond well to standard therapies.
- Trial name
- DUAL - PE (NCT07426640)
- Testing
- BoNT-A
- Where
- Saudi Arabia
- Volunteers
- 150 people
- Sponsor
- Al Mouwasat Hospital
Urinary Incontinence
Randomized Trial for Botox Urinary Incontinence
The purpose of this study is to determine how effective Botox is in reducing the amount of urine leaked and which dose of Botox is more effective and safe in those who have urinary urge incontinence.
- Trial name
- NCT00178191
- Testing
- Bladder diary, Questionnaires, Urodynamics
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Temporomandibular Joint Disorders, Temporomandibular Joint Dysfunction Syndrome
Arthrocentesis Versus Botulinum Toxin Injection in Patients With Temporomandibular Joint Disorders: A Randomized Controlled Trial
The goal of this clinical trial is to learn if arthrocentesis works as well as botulinum toxin (Botox) injection to treat pain and jaw dysfunction in adults with temporomandibular joint (TMJ) disorders.
- Conditions
- Temporomandibular Joint Disorders, Temporomandibular Joint Dysfunction Syndrome, Facial Pain
- Trial name
- RCT (NCT07736521)
- Testing
- Arthrocentesis, Botulinum Toxin-A
- Volunteers
- 66 people
- Sponsor
- Mudher MB Alsunbuli
Migraine
(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist
To compare Botox-treated and Botox-untreated symptomatic tissues (defined as areas where the head hurts and the pain is felt) of chronic migraine (CM) patients using molecular studies.
- Trial name
- NCT03381261
- Testing
- Botulinum toxin type A
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.